RJH Biosciences

RJH Biosciences is a biotechnology company based in Edmonton, Alberta, that specializes in developing novel transfection reagents and nucleic acid delivery systems. The company creates products based on cationic lipopolymers, designed to transport various nucleic acids such as plasmid DNA, siRNA, and mRNA into human cells, cell lines, and preclinical animal models. Their technology is engineered to ensure efficient cargo binding, protection from nucleases, and facilitated cellular entry through pH-buffering capabilities. Beyond their product offerings, which include specialized reagents for primary and suspension cells, the company provides R&D screening and validation services to help researchers optimize delivery for specific experimental systems.

These solutions are vital for researchers and companies working in gene medicine, immunotherapy, and oncology, where the effective delivery of nucleic acid therapeutics is a primary challenge. RJH Biosciences supports partners by tailoring delivery vehicles for clinical applications, focusing on indications such as blood and solid cancers, as well as immuno-inflammatory diseases. By offering both off-the-shelf transfection products and contract R&D services, the company enables clients to advance their gene-based therapies from laboratory research into preclinical and clinical development stages. They actively collaborate with other biotechnology and pharmaceutical firms to explore new therapeutic indications and scale up delivery system production.